Summit Therapeutics is a clinical-stage biopharmaceutical company focused on oncology drug development. Its lead program centers on ivonescimab, a PD-1/VEGF bispecific antibody advanced in partnership for non-small cell lung cancer and related indications. The business model is R&D-driven, with value tied to clinical progress and commercialization partnerships rather than current product sales.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -565.7 | — |
| Q3 2025 | 0 | — | -231.8 | — |
| Q4 2025 | 0 | — | -219.2 | — |
| Q1 2026 | 0 | — | -189.4 | — |
| Q2 2026 | 0 | — | -215.7 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Freedom Holdings Corp. (FRHC), Bio-Techne Corporation (TECH), lululemon athletica inc. (LULU), Chime Financial, Inc. (CHYM), Repligen Corporation (RGEN), Li Auto Inc. (LI)